Login Register Cart 0
Generic placeholder image

Current Indian Science

Editor-in-Chief

ISSN (Print): 2210-299X
ISSN (Online): 2210-3007

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

A Review on Obsessive Compulsive Disorder: Neurotransmitters, Biomarkers and Pharmacotherapy

Author(s): Manvi Singh, Sagarika Majhi* and RajKumari Kataria

Volume 1, 2023

Published on: 23 October, 2023

Article ID: e2210299X256025 Pages: 13

DOI: 10.2174/012210299X256025231010053232

open_access

Abstract

Around 2.5% of persons will experience obsessive-compulsive disorder (OCD), which has a significant morbidity. About 70% of individuals might have significant symptom relief with the correct medicine. Pharmacological therapy is based on a class of drugs called selective serotonin reuptake inhibitors (SSRIs). They are frequently given in higher doses and for longer durations compared to depression. Unfortunately, remission is not common. Second-line therapy that combines tricyclic clomipramine with low-dose neuroleptics is successful. For patients who are resistant to effective therapies, several augmentation procedures have been investigated, although they have not yet received strong support from controlled research. Psychotherapy and medication are frequently combined, however, thorough research has not shown that there are any synergistic benefits for adult patients. According to neuropsychological research, the development of OCD and cognitions is influenced by an imbalance in activity between the fronto-striatal circuitry's direct (excitatory) and indirect (inhibitory) pathways. A variety of anxiolytic qualities have been found in substances derived from plants that have been tested for various mental diseases. We did a detailed analysis of the pharmacological and clinical evidence of herbal medications and phytochemicals with anti-obsessive-compulsive properties using the electronic databases PubMed, Scopus, etc. to find out the status of the relevant research. The review is focused to identify the neurotransmitters involved in OCD along with the diagnostic biomarkers so as to identify the disease at an early stage and provide safe and effective pharmacotherapy. The findings showed that a number of plant remedies, comprising Withania somnifera, Silybum marianum, Echium amoenum, Crocus sativus, and Hypericum perforatum, as well as a number of natural compounds, including crocin, cannabidiol, and curcumin, have tentative low-quality evidence. The most important anti-OCD mechanism, according to existing pre-clinical studies and the need for more research to confirm its efficacy, may include manipulating the monoamine system, notably serotonin reuptake inhibition.

Keywords: Obsessive compulsive-disorder, Biomarker, Interleukin, Neurological disorder, Pharmacotherapy, Neurotransmitter.

[1]
Albelda, N.; Joel, D. Animal models of obsessive-compulsive disorder: Exploring pharmacology and neural substrates. Neurosci. Biobehav. Rev., 2012, 36(1), 47-63.
[http://dx.doi.org/10.1016/j.neubiorev.2011.04.006] [PMID: 21527287]
[2]
Albelda, N.; Bar-On, N.; Joel, D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology, 2010, 210(1), 13-24.
[http://dx.doi.org/10.1007/s00213-010-1808-9] [PMID: 20238210]
[3]
Agrati, D.; Fernández-Guasti, A.; Zuluaga, M.J.; Uriarte, N.; Pereira, M.; Ferreira, A. Compulsive-like behaviour according to the sex and the reproductive stage of female rats. Behav. Brain Res., 2005, 161(2), 313-319.
[http://dx.doi.org/10.1016/j.bbr.2005.02.017] [PMID: 15922059]
[4]
de Oliveira, K.C.; Camilo, C.; Gastaldi, V.D.; Sant’Anna Feltrin, A.; Lisboa, B.C.G.; de Jesus Rodrigues de Paula, V.; Moretto, A.C.; Lafer, B.; Hoexter, M.Q.; Miguel, E.C.; Maschietto, M.; Akiyama, É.D.; Grinberg, L.T.; Leite, R.E.P.; Suemoto, C.K.; de Lucena Ferretti-Rebustini, R.E.; Pasqualucci, C.A.; Jacob-Filho, W.; Brentani, H. Brain areas involved with obsessive-compulsive disorder present different DNA methylation modulation. BMC Genomic Data, 2021, 22(1), 45.
[http://dx.doi.org/10.1186/s12863-021-00993-0] [PMID: 34717534]
[5]
Milad, M.R.; Rauch, S.L. Obsessive-compulsive disorder: Beyond segregated cortico-striatal pathways. Trends Cogn. Sci., 2012, 16(1), 43-51.
[http://dx.doi.org/10.1016/j.tics.2011.11.003] [PMID: 22138231]
[6]
Maia, T.V.; Cooney, R.E.; Peterson, B.S. The neural bases of obsessive-compulsive disorder in children and adults. Dev. Psychopathol., 2008, 20(4), 1251-1283.
[http://dx.doi.org/10.1017/S0954579408000606] [PMID: 18838041]
[7]
Albin, R.L.; Young, A.B.; Penney, J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci., 1989, 12(10), 366-375.
[http://dx.doi.org/10.1016/0166-2236(89)90074-X] [PMID: 2479133]
[8]
Moreira, P.S.; Marques, P.; Soriano-Mas, C.; Magalhães, R.; Sousa, N.; Soares, J.M.; Morgado, P. The neural correlates of obsessive-compulsive disorder: A multimodal perspective. Transl. Psychiatry, 2017, 7(8), e1224.
[http://dx.doi.org/10.1038/tp.2017.189] [PMID: 28850108]
[9]
Melloni, M.; Urbistondo, C.; Sedeño, L.; Gelormini, C.; Kichic, R.; Ibanez, A. The extended fronto-striatal model of obsessive compulsive disorder: Convergence from event-related potentials, neuropsychology and neuroimaging. Front. Hum. Neurosci., 2012, 6, 259.
[http://dx.doi.org/10.3389/fnhum.2012.00259] [PMID: 23015786]
[10]
Pittenger, C.; Bloch, M.H.; Williams, K. Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. Pharmacol. Ther., 2011, 132(3), 314-332.
[http://dx.doi.org/10.1016/j.pharmthera.2011.09.006] [PMID: 21963369]
[11]
Menzies, L.; Chamberlain, S.R.; Laird, A.R.; Thelen, S.M.; Sahakian, B.J.; Bullmore, E.T. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: The orbitofronto-striatal model revisited. Neurosci. Biobehav. Rev., 2008, 32(3), 525-549.
[http://dx.doi.org/10.1016/j.neubiorev.2007.09.005] [PMID: 18061263]
[12]
Hansen, E.S.; Hasselbalch, S.; Law, I.; Bolwig, T.G. The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: A PET study. Int. J. Neuropsychopharmacol., 2002, 5(1), 1-10.
[http://dx.doi.org/10.1017/S1461145701002681] [PMID: 12057027]
[13]
Radua, J.; Mataix-Cols, D. Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. Br. J. Psychiatry, 2009, 195(5), 393-402.
[http://dx.doi.org/10.1192/bjp.bp.108.055046] [PMID: 19880927]
[14]
Radua, J.; van den Heuvel, O.A.; Surguladze, S.; Mataix-Cols, D. Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders. Arch. Gen. Psychiatry, 2010, 67(7), 701-711.
[http://dx.doi.org/10.1001/archgenpsychiatry.2010.70] [PMID: 20603451]
[15]
Greenberg, B.D.; Rauch, S.L.; Haber, S.N. Invasive circuitry-based neurotherapeutics: Stereotactic ablation and deep brain stimulation for OCD. Neuropsychopharmacology, 2010, 35(1), 317-336.
[http://dx.doi.org/10.1038/npp.2009.128] [PMID: 19759530]
[16]
Neurotransmitter dysregulation in OCD. In: Obsessive-compulsive Disorder: Phenomenology, Pathophysiology, and Treatment; Pittenger, C., Ed.; Oxford Academic: New York, 2017.
[http://dx.doi.org/10.1093/med/9780190228163.003.0025]
[17]
Charney, D.S.; Goodman, W.K.; Price, L.H.; Woods, S.W.; Rasmussen, S.A.; Heninger, G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch. Gen. Psychiatry, 1988, 45(2), 177-185.
[http://dx.doi.org/10.1001/archpsyc.1988.01800260095012] [PMID: 3337615]
[18]
Insel, T.R.; Mueller, E.A.; Alterman, I.; Linnoila, M.; Murphy, D.L. Obsessive-compulsive disorder and serotonin: Is there a connection? Biol. Psychiatry, 1985, 20(11), 1174-1188.
[http://dx.doi.org/10.1016/0006-3223(85)90176-3] [PMID: 2413912]
[19]
Dong, M.X.; Chen, G.H.; Hu, L. Dopaminergic system alteration in anxiety and compulsive disorders: A systematic review of neuroimaging studies. Front. Neurosci., 2020, 14, 608520.
[http://dx.doi.org/10.3389/fnins.2020.608520] [PMID: 33343291]
[20]
Pine, A.; Shiner, T.; Seymour, B.; Dolan, R.J. Dopamine, time, and impulsivity in humans. J. Neurosci., 2010, 30(26), 8888-8896.
[http://dx.doi.org/10.1523/JNEUROSCI.6028-09.2010] [PMID: 20592211]
[21]
Koo, M.S.; Kim, E.J.; Roh, D.; Kim, C.H. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev. Neurother., 2010, 10(2), 275-290.
[http://dx.doi.org/10.1586/ern.09.148] [PMID: 20136383]
[22]
Sullivan, R.M.; Talangbayan, H.; Einat, H.; Szechtman, H. Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience, 1998, 83(3), 781-789.
[http://dx.doi.org/10.1016/S0306-4522(97)00412-0] [PMID: 9483561]
[23]
Harsányi, A; Csigó, K; Demeter, G; Nemeth, A New approach to obsessive-compulsive disorder: Dopaminergic theories. Psychiatr. Hung., 2007, 22(4), 248-258.
[24]
Zor, R.; Keren, H.; Hermesh, H.; Szechtman, H.; Mort, J.; Eilam, D. Obsessive-compulsive disorder: A disorder of pessimal (non-functional) motor behavior. Acta Psychiatr. Scand., 2009, 120(4), 288-298.
[http://dx.doi.org/10.1111/j.1600-0447.2009.01370.x] [PMID: 19291081]
[25]
Bloch, HM; Coric, V; Pittenger, C New horizon in OCD Research and the potential importance glutamate. Can we develop treatment that work better and faster?; Springer, 2009.
[26]
Zachmann, M.; Tocci, P.; Nyhan, W.L. The occurrence of γ-aminobutyric acid in human tissues other than brain. J. Biol. Chem., 1966, 241(6), 1355-1358.
[http://dx.doi.org/10.1016/S0021-9258(18)96782-7] [PMID: 4222879]
[27]
Russo, AJ; Pietsch, SC Decreased hepatocyte growth factor (HGF) and gamma aminobutyric acid (GABA) in individuals with obsessive-compulsive disorder (OCD). Biomark Insights., 2013, 8, 107-14.
[28]
Owens, D.F.; Kriegstein, A.R. Is there more to gaba than synaptic inhibition? Nat. Rev. Neurosci., 2002, 3(9), 715-727.
[http://dx.doi.org/10.1038/nrn919] [PMID: 12209120]
[29]
Chakrabarty, K.; Bhattacharyya, S.; Christopher, R.; Khanna, S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology, 2005, 30(9), 1735-1740.
[http://dx.doi.org/10.1038/sj.npp.1300733] [PMID: 15841109]
[30]
Biomarkers Definitions Working Group.. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69(3), 89-95.
[http://dx.doi.org/10.1067/mcp.2001.113989] [PMID: 11240971]
[31]
Koníčková, D.; Menšíková, K.; Tučková, L.; Hényková, E.; Strnad, M.; Friedecký, D.; Stejskal, D.; Matěj, R.; Kaňovský, P. Biomarkers of neurodegenerative diseases: Biology, taxonomy, clinical relevance, and current research status. Biomedicines, 2022, 10(7), 1760.
[http://dx.doi.org/10.3390/biomedicines10071760] [PMID: 35885064]
[32]
Baldacci, F.; Mazzucchi, S.; Della Vecchia, A.; Giampietri, L.; Giannini, N.; Koronyo-Hamaoui, M.; Ceravolo, R.; Siciliano, G.; Bonuccelli, U.; Elahi, F.M.; Vergallo, A.; Lista, S.; Giorgi, F.S.; Hampel, H. The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Rev. Mol. Diagn., 2020, 20(4), 421-441.
[http://dx.doi.org/10.1080/14737159.2020.1731306] [PMID: 32066283]
[33]
Fusar-Poli, P.; Radua, J. Ten simple rules for conducting umbrella reviews. Evid. Based Ment. Health, 2018, 21(3), 95-100.
[http://dx.doi.org/10.1136/ebmental-2018-300014] [PMID: 30006442]
[34]
Fullana, M.A.; Abramovitch, A.; Via, E.; López-Sola, C.; Goldberg, X.; Reina, N.; Fortea, L.; Solanes, A.; Buckley, M.J.; Ramella-Cravaro, V.; Carvalho, A.F.; Tortella-Feliu, M.; Vieta, E.; Soriano-Mas, C.; Lázaro, L.; Stein, D.J.; Fernández de la Cruz, L.; Mataix-Cols, D.; Radua, J. Diagnostic biomarkers for obsessive-compulsive disorder: A reasonable quest or ignis fatuus? Neurosci. Biobehav. Rev., 2020, 118, 504-513.
[http://dx.doi.org/10.1016/j.neubiorev.2020.08.008] [PMID: 32866526]
[35]
Abramovitch, A.; Abramowitz, J.S.; Mittelman, A. The neuropsychology of adult obsessive-compulsive disorder: A meta-analysis. Clin. Psychol. Rev., 2013, 33(8), 1163-1171.
[http://dx.doi.org/10.1016/j.cpr.2013.09.004] [PMID: 24128603]
[36]
McKay, D.; Sookman, D.; Neziroglu, F.; Wilhelm, S.; Stein, D.J.; Kyrios, M.; Matthews, K.; Veale, D. Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder. Psychiatry Res., 2015, 225(3), 236-246.
[http://dx.doi.org/10.1016/j.psychres.2014.11.058] [PMID: 25613661]
[37]
Olatunji, B.O.; Davis, M.L.; Powers, M.B.; Smits, J.A.J. Cognitive-behavioral therapy for obsessive-compulsive disorder: A meta-analysis of treatment outcome and moderators. J. Psychiatr. Res., 2013, 47(1), 33-41.
[http://dx.doi.org/10.1016/j.jpsychires.2012.08.020] [PMID: 22999486]
[38]
Simpson, H.B.; Foa, E.B.; Liebowitz, M.R.; Ledley, D.R.; Huppert, J.D.; Cahill, S.; Vermes, D.; Schmidt, A.B.; Hembree, E.; Franklin, M.; Campeas, R.; Hahn, C.G.; Petkova, E. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. Am. J. Psychiatry, 2008, 165(5), 621-630.
[http://dx.doi.org/10.1176/appi.ajp.2007.07091440] [PMID: 18316422]
[39]
Moody, T.D.; Morfini, F.; Cheng, G.; Sheen, C.; Tadayonnejad, R.; Reggente, N.; O’Neill, J.; Feusner, J.D. Mechanisms of cognitive-behavioral therapy for obsessive-compulsive disorder involve robust and extensive increases in brain network connectivity. Transl. Psychiatry, 2017, 7(9), e1230.
[http://dx.doi.org/10.1038/tp.2017.192] [PMID: 28872637]
[40]
Feusner, J.D.; Moody, T.; Lai, T.M.; Sheen, C.; Khalsa, S.; Brown, J.; Levitt, J.; Alger, J.; O’Neill, J. Brain connectivity and prediction of relapse after cognitive-behavioral therapy in obsessive-compulsive disorder. Front. Psychiatry, 2015, 6, 74.
[http://dx.doi.org/10.3389/fpsyt.2015.00074] [PMID: 26042054]
[41]
Kahn, L.; Sutton, B.; Winston, H.R.; Abosch, A.; Thompson, J.A.; Davis, R.A. Deep brain stimulation for obsessive-compulsive disorder: Real world experience Post-FDA-Humanitarian use device approval. Front. Psychiatry, 2021, 12, 568932.
[http://dx.doi.org/10.3389/fpsyt.2021.568932] [PMID: 33868034]
[42]
Foa, E.B.; Franklin, M.E.; Moser, J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biol. Psychiatry, 2002, 52(10), 987-997.
[http://dx.doi.org/10.1016/S0006-3223(02)01552-4] [PMID: 12437939]
[43]
Vogel, P.A.; Stiles, T.C.; Götestam, K.G. Adding cognitive therapy elements to exposure therapy for obsessive compulsive disorder: A controlled study. Behav. Cogn. Psychother., 2004, 32(3), 275-290.
[http://dx.doi.org/10.1017/S1352465804001353]
[44]
Whittal, M.L.; Woody, S.R.; McLean, P.D.; Rachman, S.J.; Robichaud, M. Treatment of obsessions: A randomized controlled trial. Behav. Res. Ther., 2010, 48(4), 295-303.
[http://dx.doi.org/10.1016/j.brat.2009.11.010] [PMID: 19969286]
[45]
Calvocoressi, L.; Lewis, B.; Harris, M.; Trufan, S.J.; Goodman, W.K.; McDougle, C.J.; Price, L.H. Family accommodation in obsessive-compulsive disorder. Am. J. Psychiatry, 1995, 152(3), 441-443.
[http://dx.doi.org/10.1176/ajp.152.3.441] [PMID: 7864273]
[46]
Brown, G.W.; Rutter’, M. The measurement of family activities and relationships: A methodological study. Hum. Relat., 1966, 19(3), 241-263.
[http://dx.doi.org/10.1177/001872676601900301]
[47]
Tynes, L.L.; Salins, C.; Skiba, W.; Winstead, D.K. A psychoeducational and support group for obsessive-compulsive disorder patients and their significant others. Compr. Psychiatry, 1992, 33(3), 197-201.
[http://dx.doi.org/10.1016/0010-440X(92)90030-T] [PMID: 1591912]
[48]
Krone, K.P.; Himle, J.A.; Nesse, R.M. A standardized behavioral group treatment program for obsessive-compulsive disorder: Preliminary outcomes. Behav. Res. Ther., 1991, 29(6), 627-631.
[http://dx.doi.org/10.1016/0005-7967(91)90012-R] [PMID: 1759961]
[49]
Rees, C.S.; van Koesveld, K.E. An open trial of group metacognitive therapy for obsessive-compulsive disorder. J. Behav. Ther. Exp. Psychiatry, 2008, 39(4), 451-458.
[http://dx.doi.org/10.1016/j.jbtep.2007.11.004] [PMID: 18295186]
[50]
Kohl, S.; Schönherr, D.M.; Luigjes, J.; Denys, D.; Mueller, U.J.; Lenartz, D.; Visser-Vandewalle, V.; Kuhn, J. Deep brain stimulation for treatment-refractory obsessive compulsive disorder: A systematic review. BMC Psychiatry, 2014, 14(1), 214.
[http://dx.doi.org/10.1186/s12888-014-0214-y] [PMID: 25085317]
[51]
Holland, M.T.; Trapp, N.T.; McCormick, L.M.; Jareczek, F.J.; Zanaty, M.; Close, L.N.; Beeghly, J.; Greenlee, J.D.W. Deep brain stimulation for obsessive-compulsive disorder: A long term naturalistic follow up study in a single institution. Front. Psychiatry, 2020, 11, 55.
[http://dx.doi.org/10.3389/fpsyt.2020.00055] [PMID: 32184741]
[52]
Greenberg, B.D.; Price, L.H.; Rauch, S.L.; Friehs, G.; Noren, G.; Malone, D.; Carpenter, L.L.; Rezai, A.R.; Rasmussen, S.A. Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg. Clin. N. Am., 2003, 14(2), 199-212.
[http://dx.doi.org/10.1016/S1042-3680(03)00005-6] [PMID: 12856488]
[53]
Pepper, J.; Hariz, M.; Zrinzo, L. Deep brain stimulation versus anterior capsulotomy for obsessive-compulsive disorder: A review of the literature. J. Neurosurg., 2015, 122(5), 1028-1037.
[http://dx.doi.org/10.3171/2014.11.JNS132618] [PMID: 25635480]
[54]
Mian, M.K.; Campos, M.; Sheth, S.A.; Eskandar, E.N. Deep brain stimulation for obsessive-compulsive disorder: Past, present, and future. Neurosurg. Focus, 2010, 29(2), E10.
[http://dx.doi.org/10.3171/2010.4.FOCUS10107] [PMID: 20672912]
[55]
Nuttin, B.; Cosyns, P.; Demeulemeester, H.; Gybels, J.; Meyerson, B. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet, 1999, 354(9189), 1526.
[http://dx.doi.org/10.1016/S0140-6736(99)02376-4] [PMID: 10551504]
[56]
Haq, I.U.; Foote, K.D.; Goodman, W.G.; Wu, S.S.; Sudhyadhom, A.; Ricciuti, N.; Siddiqui, M.S.; Bowers, D.; Jacobson, C.E.; Ward, H.; Okun, M.S. Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. Neuroimage, 2011, 54(Suppl. 1), S247-S255.
[http://dx.doi.org/10.1016/j.neuroimage.2010.03.009] [PMID: 20226259]
[57]
Blomstedt, P.; Sjöberg, R.L.; Hansson, M.; Bodlund, O.; Hariz, M.I. Deep brain stimulation in the treatment of obsessive-compulsive disorder. World Neurosurg., 2013, 80(6), e245-e253.
[http://dx.doi.org/10.1016/j.wneu.2012.10.006] [PMID: 23044000]
[58]
Figee, M.; Luigjes, J.; Smolders, R.; Valencia-Alfonso, C.E.; van Wingen, G.; de Kwaasteniet, B.; Mantione, M.; Ooms, P.; de Koning, P.; Vulink, N.; Levar, N.; Droge, L.; van den Munckhof, P.; Schuurman, P.R.; Nederveen, A.; van den Brink, W.; Mazaheri, A.; Vink, M.; Denys, D. Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. Nat. Neurosci., 2013, 16(4), 386-387.
[http://dx.doi.org/10.1038/nn.3344] [PMID: 23434914]
[59]
Liebrand, L.C.; Zhutovsky, P.; Tolmeijer, E.K.; Graat, I.; Vulink, N.; de Koning, P.; Figee, M.; Schuurman, P.R.; van den Munckhof, P.; Caan, M.W.A.; Denys, D.; van Wingen, G.A. Deep brain stimulation response in obsessive-compulsive disorder is associated with preoperative nucleus accumbens volume. Neuroimage Clin., 2021, 30, 102640.
[http://dx.doi.org/10.1016/j.nicl.2021.102640] [PMID: 33799272]
[60]
Coenen, V.A.; Sajonz, B.; Reisert, M.; Bostroem, J.; Bewernick, B.; Urbach, H.; Jenkner, C.; Reinacher, P.C.; Schlaepfer, T.E.; Mädler, B. Tractography-assisted deep brain stimulation of the superolateral branch of the medial forebrain bundle (slMFB DBS) in major depression. Neuroimage Clin., 2018, 20, 580-593.
[http://dx.doi.org/10.1016/j.nicl.2018.08.020] [PMID: 30186762]
[61]
Coenen, V.A.; Schlaepfer, T.E.; Goll, P.; Reinacher, P.C.; Voderholzer, U.; Tebartz van Elst, L.; Urbach, H.; Freyer, T. The medial forebrain bundle as a target for deep brain stimulation for obsessive-compulsive disorder. CNS Spectr., 2017, 22(3), 282-289.
[http://dx.doi.org/10.1017/S1092852916000286] [PMID: 27268576]
[62]
Fineberg, N.A.; Brown, A.; Reghunandanan, S.; Pampaloni, I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol., 2012, 15(8), 1173-1191.
[http://dx.doi.org/10.1017/S1461145711001829] [PMID: 22226028]
[63]
Pittenger, C. Pharmacotherapeutic strategies and new targets in OCD. In: The Neurobiology and Treatment of OCD: Accelerating Progress; Springer: Cham, 2021; 49, pp. 331-84.
[http://dx.doi.org/10.1007/7854_2020_204]
[64]
Chouinard, G. Sertraline in the treatment of obsessive compulsive disorder: Two double-blind, placebo-controlled studies. Int. Clin. Psychopharmacol., 1992, 7(Suppl. 2), 37-41.
[http://dx.doi.org/10.1097/00004850-199210002-00007] [PMID: 1484177]
[65]
Koponen, H.; Lepola, U.; Leinonen, E.; Jokinen, R.; Penttinen, J.; Turtonen, J. Citalopram in the treatment of obsessive-compulsive disorder: An open pilot study. Acta Psychiatr. Scand., 1997, 96(5), 343-346.
[http://dx.doi.org/10.1111/j.1600-0447.1997.tb09927.x] [PMID: 9395151]
[66]
Hedges, D.W.; Woon, F.L. An emerging role for escitalopram in the treatment of obsessive-compulsive disorder. Neuropsychiatr. Dis. Treat., 2007, 3(4), 455-461.
[PMID: 19300574]
[67]
Geller, D.A.; Hoog, S.L.; Heiligenstein, J.H.; Ricardi, R.K.; Tamura, R.; Kluszynski, S.; Jacobson, J.G. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. J. Am. Acad. Child Adolesc. Psychiatry, 2001, 40(7), 773-779.
[http://dx.doi.org/10.1097/00004583-200107000-00011] [PMID: 11437015]
[68]
Hollander, E.; Friedberg, J.; Wasserman, S.; Allen, A.; Birnbaum, M.; Koran, L.M. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64(5), 546-550.
[http://dx.doi.org/10.4088/JCP.v64n0508] [PMID: 12755657]
[69]
Kamijima, K.; Murasaki, M.; Asai, M.; Higuchi, T.; Nakajima, T.; Taga, C.; Matsunaga, H. Paroxetine in the treatment of obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin. Neurosci., 2004, 58(4), 427-433.
[http://dx.doi.org/10.1111/j.1440-1819.2004.01278.x] [PMID: 15298657]
[70]
Wilson, M.; Tripp, J. Clomipramine; StatPearls: Treasure Island (FL), 2022.
[71]
Characterize the modulatory effects of dopamine D2/D3 receptor agonist and antagonist drugs on compulsive behaviors. Patent NCT00471588, 2014.
[72]
Shekhar, A. Safety study of the drug RG1068 in patients with obsessive compulsive disorder. Patent NCT00216294, 2006.
[73]
Swedo, S. Riluzole to treat child and adolescent obsessive-compulsive disorder with or without autism spectrum disorders. Patent NCT00251303, 2014.
[74]
Hollander, E. Topiramate augmentation in the treatment of obsessive-compulsive disorder. Patent NCT00211744, 2018.
[75]
Van Ameringen, M.; Patterson, B. Topiramate augmentation in a patient with obsessive-compulsive disorder. J. Psychiatry Neurosci., 2015, 40(5), E31-E32.
[http://dx.doi.org/10.1503/jpn.150100] [PMID: 26290064]
[76]
Mowla, A.; Khajeian, A.M.; Sahraian, A.; Chohedri, A.H.; Kashkoli, F. Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr., 2010, 15(11), 613-617.
[http://dx.doi.org/10.1017/S1092852912000065] [PMID: 24726048]
[77]
Feusner, J.D.; Kerwin, L.; Saxena, S.; Bystritsky, A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: An open-label trial. Psychopharmacol. Bull., 2009, 42(1), 81-93.
[PMID: 19204653]
[78]
Rodriguez, C.I.; Lapidus, K.A.B.; Zwerling, J.; Levinson, A.; Mahnke, A.; Steinman, S.A.; Kalanthroff, E.; Simpson, H.B. Challenges in testing intranasal ketamine in obsessive-compulsive disorder. J. Clin. Psychiatry, 2017, 78(4), 466-467.
[http://dx.doi.org/10.4088/JCP.16cr11234] [PMID: 28448699]
[79]
Simpson, H.B. Novel medication strategies targeting brain mechanisms in pediatric OCD. Patent NCT01695291, 2019.
[80]
Murphy, T.K.; Brennan, E.M.; Johnco, C.; Parker-Athill, E.C.; Miladinovic, B.; Storch, E.A.; Lewin, A.B. A double-blind randomized placebo-controlled pilot study of azithromycin in youth with acute-onset obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol., 2017, 27(7), 640-651.
[http://dx.doi.org/10.1089/cap.2016.0190] [PMID: 28358599]
[81]
Ayati, Z.; Sarris, J.; Chang, D.; Emami, S.A.; Rahimi, R. Herbal medicines and phytochemicals for obsessive-compulsive disorder. Phytother. Res., 2020, 34(8), 1889-1901.
[http://dx.doi.org/10.1002/ptr.6656] [PMID: 32124509]
[82]
Baratzadeh, F.; Elyasi, S.; Mohammadpour, A.H.; Salari, S.; Sahebkar, A. The role of antioxidants in the management of obsessive-compulsive disorder. Oxid. Med. Cell. Longev., 2021, 2021, 1-15.
[http://dx.doi.org/10.1155/2021/6661514]
[83]
Esalatmanesh, S.; Biuseh, M.; Noorbala, A.A.; Mostafavi, S.A.; Rezaei, F.; Mesgarpour, B.; Mohammadinejad, P.; Akhondzadeh, S. Comparison of saffron and fluvoxamine in the treatment of mild to moderate obsessive-compulsive disorder: A double blind randomized clinical trial. Iran. J. Psychiatry, 2017, 12(3), 154-162.
[PMID: 29062366]
[84]
Girdhar, S.; Wanjari, M.M.; Prajapati, S.K.; Girdhar, A. Evaluation of anti-compulsive effect of methanolic extract of Benincasa hispida Cogn. fruit in mice. Acta Pol. Pharm., 2010, 67(4), 417-421.
[PMID: 20635538]
[85]
Szejko, N.; Fremer, C.; Müller-Vahl, K.R. Cannabis improves obsessive-compulsive disorder-Case report and review of the literature. Front. Psychiatry, 2020, 11, 681.
[http://dx.doi.org/10.3389/fpsyt.2020.00681] [PMID: 32848902]
[86]
Vlad, R.A.; Hancu, G.; Ciurba, A.; Antonoaea, P.; Rédai, E.M.; Todoran, N.; Silasi, O.; Muntean, D.L. Cannabidiol - therapeutic and legal aspects. Pharmazie, 2020, 75(10), 463-469.
[PMID: 33305718]
[87]
Taylor, L.H.; Kobak, K.A. An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J. Clin. Psychiatry, 2000, 61(8), 575-578.
[http://dx.doi.org/10.4088/JCP.v61n0806] [PMID: 10982200]
[88]
Kalariya, M.; Prajapati, R.; Parmar, S.K.; Sheth, N. Effect of hydroalcoholic extract of leaves of Colocasia esculenta on marble-burying behavior in mice: Implications for obsessive-compulsive disorder. Pharm. Biol., 2015, 53(8), 1239-1242.
[http://dx.doi.org/10.3109/13880209.2015.1014923] [PMID: 25885941]
[89]
Lamanna-Rama, N.; Romero-Miguel, D.; Desco, M.; Soto-Montenegro, M.L. An update on the exploratory use of curcumin in neuropsychiatric disorders. Antioxidants, 2022, 11(2), 353.
[http://dx.doi.org/10.3390/antiox11020353] [PMID: 35204235]
[90]
Jahanbakhsh, S.P.; Manteghi, A.A.; Emami, S.A.; Mahyari, S.; Gholampour, B.; Mohammadpour, A.H.; Sahebkar, A. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial. Complement. Ther. Med., 2016, 27, 25-29.
[http://dx.doi.org/10.1016/j.ctim.2016.03.018] [PMID: 27515872]
[91]
Siani, Neha Clinical efficacy of Ashwagandha in obsessive compulsive disorder. Curr. Med. Drug Res., 2018, 2(2), Article ID: 188.
[92]
Pakseresht, S.; Boostani, H.; Sayyah, M. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: A randomized double-blind study. J. Complement. Integr. Med., 2011, 8(1), 1553-3840.
[http://dx.doi.org/10.2202/1553-3840.1465] [PMID: 22718671]
[93]
Jiji, K.; Muralidharan, P. Neuropharmacological Potential of Clitoria ternatea Linn. - A Review. Res. J. Pharma. Technol., 2020, 13(11), 5497-5502.
[94]
Shende, V.; Sahane, R.A.; Lawar, M.A.; Hamdulay, N.A.; Langote, H.A. Evaluation of anti-compulsive effect of ethanolic extract of Clitoria ternatea in mice. Asian J. Pharm. Clin. Res., 2012, 5(3), 120-123.
[95]
Prajapati, R.P.; Kalaria, M.V.; Karkare, V.P.; Parmar, S.K.; Sheth, N.R. Effect of methanolic extract of Lagenaria siceraria (Molina) Standley fruits on marble-burying behavior in mice: Implications for obsessive-compulsive disorder. Pharmacognosy Res., 2011, 3(1), 62-66.
[http://dx.doi.org/10.4103/0974-8490.79118] [PMID: 21731398]
[96]
Chanchal, R.; Balasubramaniam, A.; Navin, R.; Nadeem, S. Tabernaemontana divaricata leaves extract exacerbate burying behavior in mice. Avicenna J. Phytomed., 2015, 5(4), 282-287.
[PMID: 26445709]
[97]
Sayyah, M.; Boostani, H.; Pakseresht, S.; Malayeri, A. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(2), 362-365.
[http://dx.doi.org/10.1016/j.pnpbp.2009.12.016] [PMID: 20035818]
[98]
Grant, J.E.; Odlaug, B.L. Silymarin treatment of obsessive-compulsive spectrum disorders. J. Clin. Psychopharmacol., 2015, 35(3), 340-342.
[http://dx.doi.org/10.1097/JCP.0000000000000327] [PMID: 25874918]

Rights & Permissions Print Cite
Article Metrics
8
1
© 2024 Bentham Science Publishers | Privacy Policy